Stockreport
Incyte at Barclays: Maps Post-Jakafi Growth With New Launches and Phase III Pipeline Push [Yahoo! Finance]
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
a core business (ex-Jakafi) that was ~$1.2B in 2025 and management forecasting a 15–20% five-year CAGR toward $3–4B by 2030, supported by four near-term launches including Jakafi XR, frontline Monjuvi (DLBCL), Opzelura for moderate atopic dermatitis in Europe, and povorcitinib. INCB0989 (mCALR antibody) advancement: Early data showed high complete hematologic responses in ET and meaningful anemia improvements in 50% of MF patients, and Incyte plans at least two phase III studies this year with a subcutaneous formulation entering the clinic and intended for pivotal trials. Pivotal pipeline momentum across oncology and immunology: Incyte is progressing a JAK2 V617F program with new formulation and year-end data expected, plans a regulatory submission for Monjuvi in frontline DLBCL (submission H1 2026; possible approval late-2026/early-2027), reported ~15% responses for its TGFßR2xPD-1 bispecific in MSS colorectal (phase III started), and is moving a KRAS G12D pancreatic program towa
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | INCY | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
INCY alerts
INCY alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
NEWS
NEWS
- Incyte (INCY) had its price target lowered by UBS Group AG from $104.00 to $94.00. They now have a "neutral" rating on the stock.[MarketBeat]
- Incyte Announces Executive Leadership Appointments[Business Wire]
- Incyte (INCY) had its "buy" rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.[MarketBeat]
- Incyte (INCY) had its "overweight" rating reaffirmed by Barclays PLC.[MarketBeat]
- Incyte: An Undervalued Healthcare Gem [Seeking Alpha][Seeking Alpha]
- More
INCY
SEC Filings
SEC Filings
- 3/27/26 - Form SCHEDULE
- 3/26/26 - Form 4
- 3/26/26 - Form 8-K
- INCY's page on the SEC website
- More